Prophylactic/therapeutic agent for virus infections which comprises ala compound

A technology for infectious diseases and therapeutic agents, applied in the field of prevention and/or therapeutic agents for viral infectious diseases, can solve problems such as teratogenic effects, administration to women who cannot conceive, and inability to directly remove viruses, and achieves fewer side effects and survival rate. Improve and avoid the effect of severe aggravation

Inactive Publication Date: 2017-11-28
SBI PHARMA CO LTD
View PDF5 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Entecavir, a nucleic acid analog preparation, has been used as a therapeutic drug for hepatitis B whose main cause is hepatitis B virus infection. Entecavir targets reverse transcriptase, but since the virus cannot be directly removed, drug-resistant viruses are prone to appear. However, it is considered unsuitable for long-term administration. In addition, since this drug may induce teratogenic effects, it cannot be administered to women who may become pregnant (for example, see Non-Patent Document 2)

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Prophylactic/therapeutic agent for virus infections which comprises ala compound
  • Prophylactic/therapeutic agent for virus infections which comprises ala compound
  • Prophylactic/therapeutic agent for virus infections which comprises ala compound

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0101] (tested cells)

[0102] As a test sample, more than 70% of the mouse hepatocytes were replaced with normal human hepatocytes, so that the liver showed a metabolism close to that of the human liver. In order to infect human hepatitis B and C viruses, it was used in pharmacokinetic studies. PXB hepatocytes prepared from "PXB mouse (registered trademark)" (PhoenixBio Co., Ltd.), which is used as an in vivo prediction model of hepatitis virus infection in humans, are added to a medium such as 5-ALA, and The resulting changes in viral load were investigated.

[0103] (Preparation of medium for HBV infection)

[0104] In dHCGM medium containing 4% polyethylene glycol (DMEM+10%FBS, 44mM NaHCO 3 , 15 μg / mL of L-proline, 0.25 μg / mL of insulin, 50 μM of dexamethasone, 5 ng / mL of EGF, 0.1 mM of Asc-2P, 2% of DMSO), suspend each well as 2× 10 6 Individual hepatitis B virus (HBV) (genotype C) was prepared into 250 μL / well HBV infection medium. It should be noted that the sequen...

Embodiment 2

[0117] For a 54-year-old male patient with hepatitis B, on the 6th day of admission (taking the day of admission as day 0), oral administration of ALA phosphate containing 220 mg and sodium ferrous citrate (SFC) (ALA-SFC) 63 mg was started. ) capsules (one capsule per day), this day is regarded as the 0th day of administration. After the start of the administration, the value of total bilirubin including aspartate aminotransferase (AST) which is considered to increase in the value of blood as the destruction of liver cells progresses was measured. ), alanine aminotransferase (alanine aminotransferase: ALT), and conjugated bilirubin that is thought to leak from bile into the blood due to liver damage, and non-conjugated bilirubin that is thought to increase in value due to destruction of red blood cells type bilirubin etc. show the result in figure 2 and image 3 .

[0118] (result)

[0119] Depend on figure 2 It shows that until the 2nd day of ALA-SFC administration (t...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present invention addresses the problem of providing a prophylactic / therapeutic agent which is inexpensive, has little adverse side effects and is effective against long-term persistent virus infections. A 5-aminolevulinic acid compound represented by formula (I) (wherein R1 represents a hydrogen atom or an acyl group; and R2 represents a hydrogen atom, a linear or branched alkyl group, a cycloalkyl group, an aryl group or an aralkyl group) or a salt thereof can be used as a prophylactic / therapeutic agent for virus infections, and can prevent proliferation of viruses.

Description

technical field [0001] The present invention relates to a prophylactic and / or therapeutic agent for viral infections, and more specifically, to an agent containing 5-aminolevulinic acid (5-aminolevulinic acid, 5-ALA) or a derivative thereof or a salt thereof (these are sometimes collectively referred to as A prophylactic and / or therapeutic agent for viral infections that are "ALAs") and iron compounds. Background technique [0002] When a virus infects the body, in most cases, it is eliminated from the body by the host's immune system after infection in a short period of time, but there are also diseases that are different from the diseases caused by this temporary infection (influenza virus, etc.) , In these diseases, the infection is not eliminated from the body, but persists for a long time, and in the worst case may be transformed into a persistent infection that can lead to the death of the host (AIDS, hepatitis C, hepatitis B, etc.). [0003] For example, after the on...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/197A61K31/295A61K31/555A61K33/26A61K38/16A61P31/12A61P31/14A61P31/20A61P43/00
CPCA61K31/197A61K31/295A61K31/555A61K33/26A61K38/16A61P31/14A61P31/20A61K2300/00
Inventor 田中彻中岛元夫原武史
Owner SBI PHARMA CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap